AU Patent

AU2007260356B2 — Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Assigned to H Lundbeck AS · Expires 2013-01-24 · 13y expired

What this patent protects

Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided e.g. for the treatment of neuropathic pain.

USPTO Abstract

Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided e.g. for the treatment of neuropathic pain.

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: AU2007260356B2
Jurisdiction: AU
Classification: —
Expires: 2013-01-24
Drug substance claim: No
Drug product claim: No
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.